News
MBIO
--
0.00%
--
Mustang Bio to Present at the Raymond James Human Health Innovation Conference
Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, t...
GlobeNewswire · 1h ago
Here's Why We're Not Too Worried About Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 1d ago
8 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to ...
Benzinga · 4d ago
Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers
Mustang Bio (MBIO) announces updated interim data from Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 CD20-targeted, autologous CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas
Seekingalpha · 5d ago
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10)
Benzinga · 5d ago
Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial
Benzinga · 5d ago
BRIEF-Mustang Bio Announces Updated Interim Phase 1/2 Data For MB-106 CD20-Targeted CAR T in Patients with Chronic Lymphocytic Leukemia
reuters.com · 5d ago
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in patients treated with modified cell manufacturing process...
GlobeNewswire · 5d ago
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week, headlining the biotech news flow of the week.
Benzinga · 06/07 12:52
Mustang Bio to Host Key Opinion Leader Webinar on MB-106 CD20-Targeted CAR T for the Treatment of High-Risk B-Cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Webinar to be held Tuesday, June 15, 2021, at 1:00 p.m. ET WORCESTER, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ...
GlobeNewswire · 06/07 12:00
Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics
The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational p...
Benzinga · 06/03 12:02
Why Mustang Bio's Stock Is Trading Higher Today
Mustang Bio (NASDAQ:MBIO) shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and announced a price target from $11 per share.
Benzinga · 05/18 18:20
Surface Oncology, Mustang Bio among top picks as BTIG turns bullish on cell and gene therapy space
“We are bullish on the cell and gene therapy space,” noted BTIG analyst Justin Zelin highlighting the importance of stock picking in the area given “the limited targets and indications
Seekingalpha · 05/18 14:50
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2021
 
Benzinga · 05/18 14:05
Thinking about buying stock in Express, Mustang Bio, Senseonics, United Microelectronics, or IQIYI?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXPR, MBIO, SENS, UMC, and IQ.
PR Newswire - PRF · 05/18 13:31
BTIG Sees 260% Upside In Mustang Bio With PT of $11; Early-Stage MB-101 Starts Dosing Brain Tumor Patients
Benzinga · 05/18 13:26
Dosing underway in Mustang Bio's Phase 1 trial of MB-101 in brain tumors
The first patient has been dosed in Mustang Bio's (MBIO) Phase 1 trial to establish the safety and feasibility of administering MB-101 (autologous IL13Rα2-CAR T cells) to patients with leptomeningeal brain tumors.The
Seekingalpha · 05/18 12:27
AMC, M, IQ, and UMC among notable premarket gainers
Stealth BioTherapeutics (MITO) +31% on Q1 results.Ultralife Corporation (ULBI) +22% on new contract from U.S. Army.China HGS Real Estate Inc. (HGSH) +14% on Q2 results.XpresSpa Group (XSPA) +9% on Q1 results.Reliance Global Group (RELI)
Seekingalpha · 05/18 12:21
Mustang Bio And City Of Hope Announce First Patient Dosed In Phase 1 Clinical Trial Of MB-101 (IL13Rα2-specific CAR T cells) To Treat Leptomeningeal Brain Tumors
Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic
Benzinga · 05/18 12:16
Webull provides a variety of real-time MBIO stock news. You can receive the latest news about Mustang Bio through multiple platforms. This information may help you make smarter investment decisions.
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. The Company’s pipeline is focused in three areas: gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Its MB-102 is a CD123 CAR T cell Program for acute myeloid leukemia (AML).